{
    "nctId": "NCT03162133",
    "briefTitle": "Evaluating the Impact of Baduanjin Exercise Intervention on Quality of Life in Breast Cancer Survivors Receiving Aromatase Inhibitor Therapy",
    "officialTitle": "Evaluating the Impact of Baduanjin Exercise Intervention on Quality of Life in Breast Cancer Survivors Receiving Aromatase Inhibitor Therapy\uff1a: A Pilot Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer Survivors Receiving Aromatase Inhibitor Therapy",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 86,
    "primaryOutcomeMeasure": "Change from Baseline Quality of Life (QoL) at 3 months",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Have been diagnosed as stage I to III breast cancer 0.5 to 4.0 years before enrollment\n* Taking an AI (aromatase inhibitors )\uff0cand had been receiving an AI for at least 6 months\n\nExclusion Criteria:\n\n* A prior history of breast or any other cancer except basal or squamous cell skin cancer In\ufb02ammatory breast cancer\n* With exercise contraindications\uff1achronic obstructive pulmonary disease, uncontrolled hypertension, evidence of liver or kidney failure, symptomatic ischemic heart disease ,conditions involving the immune system such as autoimmune and/or in\ufb02ammatory diseases, cognitive impairment, alcohol/drug abuse\n* Current Baduanjin practice (within the last 6 months), and/or previous Baduanjin practice for more than 3 months\n* Women reporting 5 hours or more of vigorous physical activity per week",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}